VisiRose Selected to Present RB-PDAT at ESCRS iNovation® Day 2026 Emerging Company Showcase

PVCT subsidiary VisiRose has secured a speaking slot at ESCRS iNovation Day 2026, a major ophthalmology conference in London. The company will present its lead candidate RB-PDAT, a rose bengal sodium-based therapeutic platform targeting clinical-stage ophthalmology applications. This is a conference presentation opportunity, not a clinical milestone or regulatory advancement.

The ESCRS (European Society of Cataract and Refractive Surgeons) platform provides visibility to industry practitioners and investors focused on vision care and surgical innovation. Emerging company showcases typically attract early-stage biotech firms seeking partnerships, funding, or institutional awareness. For PVCT, the presentation extends market visibility within a specialized audience but carries limited direct commercial or clinical validation signals.

The ophthalmology and pharmaceutical development space remains competitive; conference presentations are routine components of corporate development strategy rather than material catalysts. No new efficacy, safety, or regulatory data is implied by the announcement. The timing (September 2026) is forward-looking and promotional in nature.

Sector implication: Health Care biotechnology exposure is modest. Small-cap clinical-stage biotech companies derive marginal stock momentum from conference appearances absent accompanying clinical or regulatory news. This announcement reflects standard investor relations activity rather than fundamental inflection points.